Pharmacology Core

药理学核心

• 批准号: 8643874
• 负责人: GARY A PELTZ
• 金额: $ 109.6万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-04-10 至 2019-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8643874
• 关键词: Antiviral Agents; Clinic; Collection; Data; Development; Goals; Human; In Vitro; Lead; Liver; Mus; National Institute of Allergy and Infectious Disease; Pharmaceutical Chemistry; Pharmaceutical Preparations; Pharmacology; Prodrugs; Research Infrastructure; Series; Structure-Activity Relationship; System; Therapeutic; Universities; Virus; design; drug efficacy; drug metabolism; in vivo; pathogen; pre-clinical; programs

The objective of the Pharmacology Core is to enable the projects in this Center to develop new classes of host-targeting antiviral therapeutics for the Priority viruses. The overall goal of this core is to provide the infrastructure that will enable compounds for each project to advance in pre-clinical development. This core will establish capabilities and a Center-focused collection of expertise and advisors, which are not available on the Stanford University campus or commercially. To achieve the above goals, the pharmacology core will accomplish the following specific aims, which are to provide: (i) Medicinal chemistry capabilities to produce compound series required for: characterization of lead compounds, their structure-activity-relationships, design and synthesis of pro-drugs, and analysis of drug metabolites. (ii) In vitro characterization of drug metabolism in murine and human systems. (iii) In vivo analysis of drug metabolism in conventional mice and in mice with humanized livers. (iv) In vivo analysis of drug efficacy in mice with humanized livers. (v) Biostatistical support for analysis of all data produced by the Program's projects and by the Pharmacology Core.

药理学核心的目标是使该中心的项目能够开发针对重点病毒的新型宿主靶向抗病毒治疗药物。该核心的总体目标是提供基础设施，使每个项目的化合物能够在临床前开发中取得进展。这个核心将建立一个以中心为中心的专业知识和顾问的集合，这在斯坦福大学校园或商业上是无法获得的。为了实现上述目标，药理学核心将完成以下具体目标，即提供：(i)药物化学能力，以生产化合物系列，用于：先导化合物的表征，它们的结构-活性-关系，前药的设计和合成以及药物代谢物的分析。（ii）小鼠和人体系统药物代谢的体外表征。（iii）常规小鼠和人源化肝脏小鼠体内药物代谢分析。（iv）人源化肝脏小鼠体内药效分析。生物统计学支持对方案项目和药理学核心产生的所有数据进行分析。